Spatial HLA signature may predicts response to immunotherapy in advanced renal cell carcinoma.
Nature Medicine OncoAlert #CancerResearch #oncology #kidney
nature.com/articles/s4159…

OncoAlert #OncoAlertAF #ESMOBreast24

New ESMO - Eur. Oncology guidlines in advance papillary renal cancer. While there is randomised data supporting Cabo (PFS not OS) sunitinib is still weakly supported. The single arm Len/pem & Cabo/nivo data look more active and is also recommend. 2nd line data needed ow.ly/nZA050RP77l

Updated clear cell renal cancer guidlines ESMO - Eur. Oncology.Ipi/nivo now has additional weak support in IMDC good risk (I,C). Belzutifan gets strong support in 3rd line (I,B) but less strong 2nd line (VEGF TKI preferred).1st line PD1/VEGF unchanged Annals of Oncology ow.ly/nZA050RP77l

⚡️ On Nature Medicine - A spatial architecture-embedding HLA signature to predict clinical response to immunotherapy in renal cell carcinoma

#KidneyCancer #Immunotherapy OncoAlert OncLive.com

nature.com/articles/s4159…

The OncoAlert 🚨 NEWSLETTER OUT Covering May 9-16, 2024
May, is here‼️
➡️ if you want to receive our
newsletter in your mailbox📩
OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale...
#OncoAlertAF

A must-read, in-depth concise review on mRNA-based cancer vaccines in oncology, including #lungcancer A rapidly evolving field, with first rand ph3 trials in the adjuvant and peri-operative setting currently enrolling patients!
#LCSM ESMO - Eur. Oncology ASCO IASLC OncoAlert
MSD Cosmos

🆕 🗞️ Annals of Oncology

The largest series to date on POL-E or POLD1 (proofreading-deficient) metastatic #ColorectalCancer and the use of #immunotherapy .

Tumors➡️MSS but have a very high TMB (ultra-hyper-mutated - TMB > 100 Mut/Mb).

ESMO - Eur. Oncology OncoAlert

sciencedirect.com/science/articl…

Lung cancer trials you should not miss at #ASCO24
#LCSM OncoAlert The Cancer News Oncology Brothers

Publised in Journal of Clinical Oncology
👫N=44 pts with AML-FLT3m; median age 57 yrs
💊 Crenolanib + IC
🔹CRc 86% (CR 77%)
🔹FU 45 mos ➡️ median OS not reached; median EFS 44.7 mos

#leusm OncoAlert Jayastu Senapati

ascopubs.org/doi/10.1200/JC…

Inavolisib plus fulvestrant with palbociclib was granted breakthrough therapy designation by the US FDA for PIK3CA mutant tumors with ERv+ MBC who have recurred on or within 12 months of ET. gene.com/media/press-re…

Pooled analysis do adaptive studies of Nivolumab followed by Ipilimumab in RCC. Lower rates of response conversion and CR. Upfront intensification preferred. ⁦Toni Choueiri, MD⁩ ⁦UC San Diego Health Moores Cancer Center⁩ ⁦UroToday.com⁩

Final results of RIGHT Choice: Ribociclib plus ET vs ChT in premenopausal women with clinically aggressive HR+/HER2− aBC

🔍47.7% patients had investigator-assessed visceral crisis

R+ET vs ChT
mPFS➡️21.8 vs 12.8 mo
ORR➡️66.1% vs 61.8%

OncoAlert
ascopubs.org/doi/10.1200/JC…

OncoAlert #ESMOBreast24

Excellent thread from my #lcsm friend Aakash Desai, MD, MPH on his top 5 #ASCO24 lung cancer abstracts! 🔥🫁

#ICYMI - This year’s #ASCO24 plenary session will feature THREE lung cancer trials!! OncoAlert ASCO 👇🏽👇🏽

Thoroughly looking forward to this #ASCO24 joint session with AACR, 'Drugging the ‘Undruggable’ Target: Successes, Challenges, and the Road Ahead'

The OncoAlert🚨NEWSLETTER OUT
Covering May 9-16 , 2024

REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale…

Today’s the deadline to submit your abstracts for #ASCOQLTY24 !
Please share your work with your colleagues to improve cancer care!
Oncology Nursing Society OncoAlert

Don’t forget: the deadline to apply for Patient Partner registration at #MASCC24 is May 24, 2024.

Visit our website for the full eligibility criteria and instructions on how to apply: mascc.org/annualmeeting2…

#supponc OncoAlert

📣 We're hosting a Meet and Greet at #ASCO24 with our #SoMe Editor Gil Morgan, MD (@OncoAlert) and Section Editors Dr. Daniel Morgensztern of Washington U. Med and Walter Stadler of UChicago Medicine! Plan a stop by the American Cancer Society booth at 4pm on Sunday right after the ASCO Plenary.